{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:45:29Z","timestamp":1779889529814,"version":"3.53.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01625-6","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:11:01Z","timestamp":1767802261000},"page":"911-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Scott","family":"Gottlieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Farberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Barghout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"9","key":"1625_CR1","first-page":"626","volume":"87","author":"N Weigle","year":"2013","unstructured":"Weigle N, McBane S. Psoriasis. Am Fam Phys. 2013;87(9):626\u201333.","journal-title":"Am Fam Phys"},{"issue":"5","key":"1625_CR2","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"7130","key":"1625_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nature05663","volume":"445","author":"MA Lowes","year":"2007","unstructured":"Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866\u201373.","journal-title":"Nature"},{"issue":"4","key":"1625_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"key":"1625_CR5","unstructured":"ILUMYA\u00ae (tildrakizumab-asmn) injection, for subcutaneous use. Full Prescribing Information. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2025."},{"issue":"10091","key":"1625_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE\u00a01 and reSURFACE\u00a02): results from two randomised controlled, phase\u00a03 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"10","key":"1625_CR7","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s13555-022-00793-z","volume":"12","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5\u00a0years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325\u201341.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1625_CR8","unstructured":"European Medicines Agency. Ilumetri. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri. Accessed 30 September 2025."},{"issue":"6","key":"1625_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","volume":"29","author":"J Bilal","year":"2018","unstructured":"Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29(6):569\u201378.","journal-title":"J Dermatolog Treat"},{"key":"1625_CR10","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"F Bai","year":"2019","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, Tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.","journal-title":"J Immunol Res"},{"issue":"3","key":"1625_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1625_CR12","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1007\/s12325-022-02065-w","volume":"39","author":"CL Leonardi","year":"2022","unstructured":"Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256\u201369.","journal-title":"Adv Ther"},{"key":"1625_CR13","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for systematic reviews of interventions version 6.4 (updated 2023 August): Oxford: The Cochrane Collaboration; 2020. www.training.cochrane.org\/handbook. Accessed 30 Sept 2025."},{"key":"1625_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1625_CR15","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2014. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 30 Sept 2025."},{"key":"1625_CR16","unstructured":"Joanna Briggs Institute. Critical appraisal tools: checklist for analytical cross-sectional studies 2022. https:\/\/jbi.global\/critical-appraisal-tools. Accessed 30 Sept 2025."},{"key":"1625_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1741-7015-12-93","volume":"12","author":"S Cope","year":"2014","unstructured":"Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:93.","journal-title":"BMC Med"},{"key":"1625_CR18","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JJ Deeks","year":"2023","unstructured":"Deeks JJ, Higgins JPT. Chapter 10 Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions. UK: Cochrane Statistical Methods Group; 2023."},{"issue":"suppl 1","key":"1625_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00266-022-02977-6","volume":"47","author":"Y Chen","year":"2023","unstructured":"Chen Y, Chen D, Wang Y, Han Y. Using Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Aesth Plast Surg. 2023;47(suppl 1):83\u20134.","journal-title":"Aesth Plast Surg"},{"issue":"2","key":"1625_CR20","doi-asserted-by":"publisher","first-page":"e15228","DOI":"10.1111\/dth.15228","volume":"35","author":"A Narcisi","year":"2022","unstructured":"Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1625_CR21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","volume":"23","author":"T Torres","year":"2022","unstructured":"Torres T, Puig L, Vender R, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891\u2013904.","journal-title":"Am J Clin Dermatol"},{"key":"1625_CR22","volume-title":"Polymorphism study as biomarkers of response to tildrakizumab","author":"BB Bris","year":"2023","unstructured":"Bris BB, De la Fuente H, del Mar Llamas Velasco M, et al. Polymorphism study as biomarkers of response to tildrakizumab. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"key":"1625_CR23","volume-title":"Real-world effectiveness of tildrakizumab in a UK cohort: a drug survival analysis","author":"A Downs","year":"2023","unstructured":"Downs A, Barea A, Cammish G, et al. Real-world effectiveness of tildrakizumab in a UK cohort: a drug survival analysis. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"issue":"suppl 3","key":"1625_CR24","doi-asserted-by":"publisher","first-page":"AB27","DOI":"10.1016\/j.jaad.2022.06.141","volume":"87","author":"N Kahen","year":"2022","unstructured":"Kahen N, Ali Y, West DP. Cerebrovascular accident events associated with IL-23 inhibition: pharmacovigilance analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) from the RADAR (Research on Adverse Drug Events And Reports) program. J Am Acad Dermatol. 2022;87(suppl 3):AB27.","journal-title":"J Am Acad Dermatol"},{"key":"1625_CR25","volume-title":"Psoriasis of the scalp, genital area, and palmoplantar psoriasis: efficacy of modern biologics drugs in difficult-to-treat areas","author":"L Burzi","year":"2023","unstructured":"Burzi L, Mastorino L, Dapavo P, Ribero S, Quaglino P. Psoriasis of the scalp, genital area, and palmoplantar psoriasis: efficacy of modern biologics drugs in difficult-to-treat areas. Singapore: 25th World Congress of Dermatology; 2023."},{"issue":"10","key":"1625_CR26","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s13555-022-00800-3","volume":"12","author":"G Becher","year":"2022","unstructured":"Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343\u201354.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"1625_CR27","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1111\/jdv.19468","volume":"37","author":"S Berenguer-Ruiz","year":"2023","unstructured":"Berenguer-Ruiz S, Aparicio-Dom\u00ednguez M, Herranz-Pinto P, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24\u00a0weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2023;37(12):2517\u201325.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1625_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/ph16040526","volume":"16","author":"E Campione","year":"2023","unstructured":"Campione E, Lambiase S, Gaeta Shumak R, et al. A real-life study on the use of tildrakizumab in psoriatic patients. Pharmaceuticals (Basel). 2023;16(4):526.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"1625_CR29","doi-asserted-by":"publisher","first-page":"AB237","DOI":"10.1016\/j.jaad.2023.07.947","volume":"89","author":"S Khattri","year":"2023","unstructured":"Khattri S, Gooderham M, Reich A, et al. The Psoriasis Study of Health Outcomes (PSoHO) in biologic-naive and -experienced patients: a post-hoc analysis of patients receiving treatment according to US labels. J Am Acad Dermatol. 2023;89(3):AB237.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1625_CR30","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/jdv.18376","volume":"36","author":"A Pinter","year":"2022","unstructured":"Pinter A, Puig L, Sch\u00e4kel K, et al. Comparative effectiveness of biologics in clinical practice: week\u00a012 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087\u2013100.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1625_CR31","doi-asserted-by":"publisher","first-page":"2133531","DOI":"10.1080\/09546634.2022.2133531","volume":"34","author":"CDB Elgaard","year":"2023","unstructured":"Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2023;34(1):2133531.","journal-title":"J Dermatolog Treat"},{"key":"1625_CR32","volume-title":"Real-world effectiveness of interleukin-23 inhibitors in plaque psoriasis in patients from a tertiary dermatology centre","year":"2023","unstructured":"Grabowski K, Narbutt J, Lesiak A, Skibi\u0144ska M, Noweta M, editors. Real-world effectiveness of interleukin-23 inhibitors in plaque psoriasis in patients from a tertiary dermatology centre. Seville: European Academy of Dermatology and Venerology Congress; 2023."},{"issue":"1","key":"1625_CR33","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1038\/s41598-022-18790-9","volume":"12","author":"T Graier","year":"2022","unstructured":"Graier T, Weger W, Jonak C, et al. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep. 2022;12(1):15078.","journal-title":"Sci Rep"},{"key":"1625_CR34","first-page":"A74","volume":"30","author":"A Merch\u00e1n","year":"2023","unstructured":"Merch\u00e1n A, Luc\u00eda SC, Raquel FM, et al. Comparison of the effectiveness between interleukin-23 inhibitors for treatment of psoriasis in a third level hospital. Eur J Clin Pharm. 2023;30:A74.","journal-title":"Eur J Clin Pharm"},{"issue":"11","key":"1625_CR35","doi-asserted-by":"publisher","first-page":"e15793","DOI":"10.1111\/dth.15793","volume":"35","author":"F Ricceri","year":"2022","unstructured":"Ricceri F, Chiricozzi A, Peris K, Prignano F. Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: a multicentric retrospective study. Dermatol Ther. 2022;35(11):e15793.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1625_CR36","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813\u201320.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1625_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/ced.14979","volume":"47","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"1625_CR38","unstructured":"TREMFYA\u00ae (guselkumab) injection, for subcutaneous or intravenous use. Full Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2025."},{"key":"1625_CR39","unstructured":"SKYRIZI\u00ae (risankizumab-rzaa) injection, for subcutaneous or intravenous use. Full Prescribing Information. North Chicago, IL: AbbVie Inc.; 2025."},{"key":"1625_CR40","volume-title":"IL23 inhibitors in psoriasis-case series","year":"2023","unstructured":"Rodica O, Ana-Maria C, Maria-Magdalena C, editors. IL23 inhibitors in psoriasis-case series. Singapore: 25th World Congress of Dermatology; 2023."},{"key":"1625_CR41","volume-title":"Tildrakizumab in the treatment of moderate to severe plaque psoriasis: 52\u00a0weeks of real-world experience in the Valencian Community","year":"2023","unstructured":"Alarcon SS, Ramos FJM, Diaz JM, et al, editors. Tildrakizumab in the treatment of moderate to severe plaque psoriasis: 52\u00a0weeks of real-world experience in the Valencian Community. Milan: European Academy of Dermatology and Venereology Congress; 2023."},{"issue":"8","key":"1625_CR42","doi-asserted-by":"publisher","first-page":"766","DOI":"10.36849\/jdd.6830","volume":"22","author":"J Bagel","year":"2023","unstructured":"Bagel J, Novak K, Nelson E. Tildrakizumab in combination with topical halcinonide 0.1% ointment for treating moderate to severe plaque psoriasis. J Drugs Dermatol. 2023;22(8):766\u201372.","journal-title":"J Drugs Dermatol"},{"key":"1625_CR43","volume-title":"Real-life experience with tildrakizumab in our clinical practice","year":"2023","unstructured":"Baratta S, Mortato E, Viola R, Poli MA, De Caro AP, Loconsole F, editors. Real-life experience with tildrakizumab in our clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"issue":"suppl 4","key":"1625_CR44","first-page":"ljad113. 35","volume":"188","author":"G Becher","year":"2023","unstructured":"Becher G, Stephen K, McInnes A, et al. Clinical priorities when treating psoriasis: insights from a real-world data study of tildrakizumab. Br J Dermatol. 2023;188(suppl 4):ljad113. 35.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1625_CR45","doi-asserted-by":"publisher","first-page":"AB199","DOI":"10.1016\/j.jaad.2022.06.826","volume":"87","author":"N Bhatia","year":"2022","unstructured":"Bhatia N, Heim J, Torres M, Beute P, Rozzo SJ, Vasquez JG. Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: week\u00a028 interim analysis of a phase\u00a04 study. J Am Acad Dermatol. 2022;87(3):AB199.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1625_CR46","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.jval.2023.03.2445","volume":"26","author":"N Bhatia","year":"2023","unstructured":"Bhatia N, Vasquez JG, Schenkel B, Rozzo SJ, Heim J. Real-world effectiveness and safety in a phase\u00a04 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis. Value Health. 2023;26(6):S57.","journal-title":"Value Health"},{"issue":"3","key":"1625_CR47","doi-asserted-by":"publisher","first-page":"AB216","DOI":"10.1016\/j.jaad.2023.07.865","volume":"89","author":"N Bhatia","year":"2023","unstructured":"Bhatia N, Vasquez JG, Schenkel B, Rozzo SJ, Heim J. Real-world effectiveness of tildrakizumab in a phase\u00a04 study in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2023;89(3):AB216.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1625_CR48","doi-asserted-by":"publisher","first-page":"2200872","DOI":"10.1080\/09546634.2023.2200872","volume":"34","author":"N Bhatia","year":"2023","unstructured":"Bhatia N, Heim J, Schenkel B, Vasquez JG. Quality of life and patient-reported symptoms in a phase\u00a04, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: week\u00a028 interim analysis. J Dermatolog Treat. 2023;34(1):2200872.","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"1625_CR49","doi-asserted-by":"publisher","first-page":"754","DOI":"10.36849\/jdd.7471","volume":"22","author":"J Heim","year":"2023","unstructured":"Heim J, Vasquez JG, Schenkel B, Bhatia N. Real-world effectiveness and safety of tildrakizumab in patients with moderate-to-severe psoriasis: week\u00a028 interim analysis of a phase\u00a04 study. J Drugs Dermatol. 2023;22(8):754\u201360.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1625_CR50","doi-asserted-by":"publisher","first-page":"AB85","DOI":"10.1016\/j.jaad.2023.07.344","volume":"89","author":"JG Vasquez","year":"2023","unstructured":"Vasquez JG, Bhatia N, Schenkel B, Rozzo SJ, Heim J. Safety of tildrakizumab in a phase\u00a04 real-world study in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2023;89(3):AB85.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1625_CR51","doi-asserted-by":"publisher","first-page":"AB204","DOI":"10.1016\/j.jaad.2023.07.819","volume":"89","author":"J Heim","year":"2023","unstructured":"Heim J, Vasquez JG, Rozzo SJ, Schenkel B, Bhatia N. Patients\u2019 quality of life in a phase\u00a04 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2023;89(3):AB204.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1625_CR52","doi-asserted-by":"publisher","first-page":"914","DOI":"10.36849\/JDD.6828","volume":"21","author":"A Brunasso","year":"2022","unstructured":"Brunasso A. Nail psoriasis improvement during tildrakizumab therapy: a real-life experience. J Drugs Dermatol. 2022;21(8):914\u20136.","journal-title":"J Drugs Dermatol"},{"key":"1625_CR53","first-page":"2021-6-8","volume":"10","author":"M Burlando","year":"2021","unstructured":"Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:2021-6\u20138.","journal-title":"Drugs Context"},{"issue":"18","key":"1625_CR54","first-page":"6772","volume":"26","author":"M Burlando","year":"2022","unstructured":"Burlando M, Maul JT, Salvi I, et al. Psoriasis patients\u2019 characteristics associated with high PASI response to tildrakizumab: an international dual center study. Eur Rev Med Pharmacol Sci. 2022;26(18):6772\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"1625_CR55","first-page":"e15488","volume":"35","author":"G Caldarola","year":"2022","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6):e15488.","journal-title":"Dermatol Ther"},{"key":"1625_CR56","volume-title":"A real life clinical experience of tildrakizumab in patients affected by psoriasis and metabolic comorbidities","author":"S Lambiase","year":"2023","unstructured":"Lambiase S, Shumak RG, Lanna C, et al. A real life clinical experience of tildrakizumab in patients affected by psoriasis and metabolic comorbidities. Singapore: 25th World Congress of Dermatology; 2023."},{"key":"1625_CR57","volume-title":"Tildrakizumab improves symptoms of pruritus, pain, and scaling in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice","author":"A Costanzo","year":"2022","unstructured":"Costanzo A, Cuccia A, Daud\u00e9n E, et al. Tildrakizumab improves symptoms of pruritus, pain, and scaling in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Milan: European Academy of Dermatology and Venereology Congress; 2022."},{"key":"1625_CR58","volume-title":"Super responders to tildrakizumab treatment in moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, Cuccia A, Daud\u00e9n E, et al. Super responders to tildrakizumab treatment in moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"key":"1625_CR59","volume-title":"Tildrakizumab demonstrates high efficacy and a favourable safety profile in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, Cuccia A, Daud\u00e9n E, et al. Tildrakizumab demonstrates high efficacy and a favourable safety profile in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Singapore: World Congress of Dermatology; 2023."},{"key":"1625_CR60","volume-title":"Tildrakizumab demonstrates high efficacy regardless of baseline characteristics in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, Cuccia A, Dauden E, et al. Tildrakizumab demonstrates high efficacy regardless of baseline characteristics in patients with moderate-to-severe chronic plaque psoriasis in conditions close to real clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"issue":"10","key":"1625_CR61","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jdv.19229","volume":"37","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, Llamas-Velasco M, Fabbrocini G, et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol. 2023;37(10):2004\u201315.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1625_CR62","doi-asserted-by":"publisher","first-page":"e2023215","DOI":"10.5826\/dpc.1304a215","volume":"13","author":"EV Di Brizzi","year":"2023","unstructured":"Di Brizzi EV, Buononato D, Benvenuto P, et al. Effectiveness and safety after a switch to tildrakizumab: a real world multicenter Italian study in psoriasis. Dermatol Pract Concept. 2023;13(4):e2023215.","journal-title":"Dermatol Pract Concept"},{"key":"1625_CR63","volume-title":"Tildrakizumab in psoriasis: extended real world data from a prospective cohort study (KTC)","author":"K Drerup","year":"2023","unstructured":"Drerup K, Seemann C, Gerdes S, Mrowiet U. Tildrakizumab in psoriasis: extended real world data from a prospective cohort study (KTC). Singapore: 25th World Congress of Dermatology; 2023."},{"issue":"4","key":"1625_CR64","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000519924","volume":"238","author":"KA Drerup","year":"2022","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238(4):615\u20139.","journal-title":"Dermatology"},{"key":"1625_CR65","volume-title":"Tildrakizumab experience in real clinical practice","year":"2023","unstructured":"Escalas J, Palos CM, Ramos AL, editors. Tildrakizumab experience in real clinical practice. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"key":"1625_CR66","volume-title":"Real-world evidence of effectiveness and safety of tildrakizumab in patients with moderate to severe psoriasis from 8\u00a0hospitals","year":"2023","unstructured":"Fornons-Servent R, Ferrer AL, Vilarrasa E, et al editors. Real-world evidence of effectiveness and safety of tildrakizumab in patients with moderate to severe psoriasis from 8\u00a0hospitals. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"issue":"9","key":"1625_CR67","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.3390\/jcm11092631","volume":"11","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631.","journal-title":"J Clin Med"},{"issue":"1","key":"1625_CR68","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jvc2.65","volume":"2","author":"A Gambardella","year":"2023","unstructured":"Gambardella A, Licata G, De Rosa A, Calabrese G, Alfano R, Argenziano G. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. JEADV Clin Pract. 2023;2(1):52\u20138.","journal-title":"JEADV Clin Pract"},{"issue":"11","key":"1625_CR69","doi-asserted-by":"publisher","first-page":"e15818","DOI":"10.1111\/dth.15818","volume":"35","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Cariti C, Susca S, et al. Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement. Dermatol Ther. 2022;35(11):e15818.","journal-title":"Dermatol Ther"},{"key":"1625_CR70","unstructured":"Maul J-T, Steinmann S, Rosset N, et al editors. Management of moderate-to-severe psoriasis with tildrakizumab: first real-world-evidence results in a Swiss patient cohort from the SDNTT registry. Geneva: Schweizerische Gesellschaft f\u00fcr Dermatologie und Venerologie; 2021."},{"issue":"1","key":"1625_CR71","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.18594","volume":"37","author":"A Narcisi","year":"2023","unstructured":"Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study\u2014IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93\u2013103.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1625_CR72","volume-title":"Tildrakizumab: efficacy and safety in mid-term (52\u00a0weeks) on real clinical practice in 32 patients with moderate-to-severe psoriasis","year":"2023","unstructured":"Rodriguez Fernandez-Freire L, Ortiz J, Hernandez JC, Morillo M, Barabash R, Conejo-Mir J, editors. Tildrakizumab: efficacy and safety in mid-term (52\u00a0weeks) on real clinical practice in 32 patients with moderate-to-severe psoriasis. Singapore: 25th World Congress of Dermatology; 2023."},{"issue":"12","key":"1625_CR73","doi-asserted-by":"publisher","first-page":"e15941","DOI":"10.1111\/dth.15941","volume":"35","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941.","journal-title":"Dermatol Ther"},{"key":"1625_CR74","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2147\/CCID.S402183","volume":"16","author":"A Ruggiero","year":"2023","unstructured":"Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52\u00a0weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529\u201336.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"17","key":"1625_CR75","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.3390\/jcm11175098","volume":"11","author":"R Ruiz-Villaverde","year":"2022","unstructured":"Ruiz-Villaverde R, Rodriguez Fernandez-Freire L, Font-Ugalde P, Galan-Gutierrez M. Tildrakizumab: efficacy, safety and survival in mid-term (52\u00a0weeks) in three tertiary hospitals in Andalucia (Spain). J Clin Med. 2022;11(17):5098.","journal-title":"J Clin Med"},{"key":"1625_CR76","volume-title":"Real-world effectiveness, quality of life, and treatment satisfaction with tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase\u00a0IV POSITIVE study","author":"M Augustin","year":"2023","unstructured":"Augustin M, Sommer R, Reguiai Z, et al. Real-world effectiveness, quality of life, and treatment satisfaction with tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase\u00a0IV POSITIVE study. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"key":"1625_CR77","volume-title":"Real-world safety of tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase\u00a0IV POSITIVE study","author":"U Mrowietz","year":"2023","unstructured":"Mrowietz U, Sommer R, Reguiai Z, et al. Real-world safety of tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase\u00a0IV POSITIVE study. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"key":"1625_CR78","volume-title":"Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data of the phase\u00a0IV POSITIVE study","author":"R Sommer","year":"2023","unstructured":"Sommer R, Augustin M, Reguiai Z, et al. Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data of the phase\u00a0IV POSITIVE study. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"key":"1625_CR79","volume-title":"Tildrakizumab improves quality of life in patients with moderate-to-severe chronic plaque psoriasis in a real-life setting","author":"A Tsianakas","year":"2022","unstructured":"Tsianakas A, Ostendorf R, Diemert S, Asadullah K. Tildrakizumab improves quality of life in patients with moderate-to-severe chronic plaque psoriasis in a real-life setting. Milan: European Academy of Dermatology and Venereology Congress; 2022."},{"issue":"1","key":"1625_CR80","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jdv.18572","volume":"37","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37(1):85\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1625_CR81","volume-title":"Sustained efficacy and safety of tildrakizumab over 2\u00a0years in patients with moderate to severe plaque psoriasis in routine clinical practice: interim results in week\u00a0100 from the non-interventional, prospective, multicenter study TILOT","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, Kirsch A, Petri M. Sustained efficacy and safety of tildrakizumab over 2\u00a0years in patients with moderate to severe plaque psoriasis in routine clinical practice: interim results in week\u00a0100 from the non-interventional, prospective, multicenter study TILOT. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"key":"1625_CR82","volume-title":"Tildrakizumab improves signs and symptoms in patients with moderate to severe plaque psoriasis in a realworld setting: a holistic approach","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, Kirsch A, Schwichtenberg U. Tildrakizumab improves signs and symptoms in patients with moderate to severe plaque psoriasis in a realworld setting: a holistic approach. Berlin: European Academy of Dermatology and Venereology Congress; 2023."},{"issue":"2","key":"1625_CR83","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/24755303221077211","volume":"7","author":"NW Wei","year":"2022","unstructured":"Wei NW, Chi S, Lebwohl MG. Retrospective analysis in patients with moderate to severe plaque psoriasis treated with tildrakizumab: real-life clinical data. J Psoriasis Psoriatic Arthritis. 2022;7(2):55\u20139.","journal-title":"J Psoriasis Psoriatic Arthritis"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01625-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:02:56Z","timestamp":1772006576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01625-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1625"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01625-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Scott Gottlieb serves as a consultant and advisory board member for Bristol Myers Squibb, Janssen, Lilly, Sun Pharmaceutical Industries Limited, and UCB. Aaron S. Farberg has been an advisor for Amgen, Apogee, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Feldan, Galderma, Incyte, Janssen, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Sun Pharma. Neal Bhatia is an advisor, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, EPI Health, Ferndale, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and Verrica Pharmaceuticals. Mir Sohail Fazeli, Kimberly Hofer, and Otto Lam report employment with Evidinno Outcomes Research Inc. Victoria Barghout is CEO of Viver Health LLC, which receives funding from Bristol Myers Squibb, Novartis, Sun Pharma, and Taiho Pharmaceutical Co. Jacob Mathew reports employment with Sun Pharmaceutical Industries, Inc. Thomas J Ferro reports past employment with Sun Pharmaceutical Industries, Inc., and current employment with Data Loft, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not include any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}